polygenic risk score
Can.Heal has produced a dozen reports that will inform both EU policies and national health strategies for personalized cancer treatment and prevention going forward.
Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.
Biobanks have been making strides in gathering data from more diverse populations this year while the evidence for the clinical utility of embryo PRS testing remains insufficient.
Southern Research, MyOme, and Broad Clinical Labs will use $25 million in grants to provide genetic testing and counselling to up to 30,000 state residents.
MyOme, Broad Clinical Labs Supporting Genetics-Based Personalized Health Risk Program in Alabama
The Catalyst program, conducted by nonprofit Southern Research, aims to bring genetics-driven clinical risk assessments to patients in Alabama free of charge.